Fumihiro Sanada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4180845/publications.pdf

Version: 2024-02-01

21 1,018 17 21 papers citations h-index g-index

21 21 21 1797 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Periostin Short Fragment with Exon 17 via Aberrant Alternative Splicing Is Required for Breast Cancer Growth and Metastasis. Cells, 2021, 10, 892.	4.1	6
2	Periostin Exon-21 Antibody Neutralization of Triple-Negative Breast Cancer Cell-Derived Periostin Regulates Tumor-Associated Macrophage Polarization and Angiogenesis. Cancers, 2021, 13, 5072.	3.7	3
3	Progress of Gene Therapy in Cardiovascular Disease. Hypertension, 2020, 76, 1038-1044.	2.7	16
4	Therapeutic Angiogenesis Using HGF Plasmid. Annals of Vascular Diseases, 2020, 13, 109-115.	0.5	14
5	Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Scientific Reports, 2018, 8, 4013.	3.3	26
6	Source of Chronic Inflammation in Aging. Frontiers in Cardiovascular Medicine, 2018, 5, 12.	2.4	267
7	IGF Binding Protein-5 Induces Cell Senescence. Frontiers in Endocrinology, 2018, 9, 53.	3.5	33
8	Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice. Scientific Reports, 2017, 7, 130.	3.3	28
9	Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence. Scientific Reports, 2017, 7, 17172.	3.3	35
10	Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5. Scientific Reports, 2016, 6, 35580.	3.3	24
11	Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-1 ³ and cAMP Pathways in Vascular Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 545-552.	2.4	31
12	Selective Blockade of Periostin Exon 17 Preserves Cardiac Performance in Acute Myocardial Infarction. Hypertension, 2016, 67, 356-361.	2.7	56
13	Hepatocyte Growth Factor Inhibits Lipopolysaccharide-Induced Oxidative Stress via Epithelial Growth Factor Receptor Degradation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2687-2693.	2.4	26
14	Hepatocyte Growth Factor Reduces Cardiac Fibrosis by Inhibiting Endothelial-Mesenchymal Transition. Hypertension, 2012, 59, 958-965.	2.7	85
15	Telmisartan Exerts Renoprotective Actions via Peroxisome Proliferator-Activated Receptor-Î ³ /Hepatocyte Growth Factor Pathway Independent of Angiotensin II Type 1 Receptor Blockade. Hypertension, 2012, 59, 308-316.	2.7	44
16	Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. International Journal of Molecular Medicine, 2011, 28, 181-6.	4.0	84
17	Hepatocyte Growth Factor Attenuates Transforming Growth Factor- \hat{l}^2 -Angiotensin II Crosstalk Through Inhibition of the PTEN/Akt Pathway. Hypertension, 2011, 58, 190-196.	2.7	26
18	Hepatocyte growth factor attenuates renal fibrosis through TGF- \hat{l}^2l suppression by apoptosis of myofibroblasts. Journal of Hypertension, 2010, 28, 2454-2461.	0.5	53

Fumihiro Sanada

#	Article	lF	CITATION
19	Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells. Circulation Research, 2009, 105, 667-675.	4.5	41
20	Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II–Induced Endothelial Progenitor Cell Senescence. Hypertension, 2009, 53, 77-82.	2.7	56
21	Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin. Hypertension, 2007, 49, 1409-1414.	2.7	64